Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  European Heart Journal

• Publication date

  2013-11-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurheartj/eht032PMID 23391580
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics.

  2013cited by this paper
• Circulating MicroRNAs as Novel Biomarkers for Platelet Activation

  2013cited by this paper
• Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.

  2013cited by this paper
• Circulating microRNAs: From single biomarkers to re-wired networks

  2012cited by this paper
• Serum levels of microRNAs in patients with heart failure

  2012cited by this paper
• Prospective study on circulating MicroRNAs and risk of myocardial infarction.

  2012cited by this paper
• Analytical challenges and technical limitations in assessing circulating MiRNAs

  2012cited by this paper
• von Willebrand Factor: More Than a Regulator of Hemostasis and Thrombosis

  2012cited by this paper
• Profiling of circulating microRNAs: from single biomarkers to re-wired networks

  2011cited by this paper
• Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome.

  2011cited by this paper
• microRNAs in heart disease: putative novel therapeutic targets?

  2010cited by this paper
• Circulating MicroRNAs in Patients With Coronary Artery Disease

  2010cited by this paper
• Plasma MicroRNA Profiling Reveals Loss of Endothelial MiR-126 and Other MicroRNAs in Type 2 Diabetes

  2010cited by this paper
• Circulating microRNAs as potential biomarkers of coronary artery disease: a promise to be fulfilled?

  2010cited by this paper
• MicroRNAs and cardiac pathology

  2009cited by this paper

• RNA therapeutics for treatment of diabetes.

  2024cites this paper
• Zhilong Huoxue Tongyu capsule ameliorates platelet aggregation and thrombus induced by aspirin in rats by regulating lipid metabolism and microRNA pathway.

  2023cites this paper
• Long-Term Sports Practice and Atrial Fibrillation: An Updated Review of a Complex Relationship

  2023cites this paper
• MicroRNAs in Kawasaki disease: An update on diagnosis, therapy and monitoring

  2022cites this paper
• Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target

  2022cites this paper
• MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus

  2021cites this paper
• MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty

  2021cites this paper
• Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements

  2020cites this paper
• Diagnostic and theranostic microRNAs in the pathogenesis of atherosclerosis

  2020cites this paper
• Modulation of microRNAs by aspirin in cardiovascular disease.

  2020cites this paper
• Pre-diagnostic role of platelet miRNA in coronary heart disease of healthy overweight subjects via platelet leptin receptor activation

  2019cites this paper
• The Role of Platelets in Diabetes Mellitus

  2019cites this paper
• Clinical-pathological correlations of BAV and the attendant thoracic aortopathies. Part 2: Pluridisciplinary perspective on their genetic and molecular origins.

  2019cites this paper
• Platelet microRNAs in hypertensive patients with and without cardiovascular disease

  2018cites this paper
• microRNAs, Angiogenesis and Atherosclerosis

  2017cites this paper
• Circulating microRNAs as Novel Biomarkers in Cardiovascular Disease: Basic and Technical Principles

  2017cites this paper
• Non-coding RNAs in the Vasculature

  2017cites this paper
• The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.

  2017cites this paper
• MicroRNAs in Coronary Heart Disease: Ready to Enter the Clinical Arena?

  2016cites this paper
• The role of microRNAs in prethrombotic status associated with coronary artery disease

  2016cites this paper
• A brief review on the mechanisms of aspirin resistance.

  2016cites this paper
• microRNAs in cardiovascular diseases: current knowledge and the road ahead.

  2014cites this paper
• Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease

  2013cites this paper
• Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

  2013cites this paper